Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results, Misses Estimates By $0.23 EPS

Definium Therapeutics (NASDAQ:DFTX) released its earnings results on Thursday. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Three pivotal DT120 ODT phase III readouts are imminent — EMERGE (MDD) top-line later this quarter, and VOYAGE and PANORAMA (both GAD) expected in early and late Q3 respectively, with Breakthrough Therapy designation for DT120 in GAD and an NDA submission planned subject to positive data.
• All pivotal trials are near complete (EMERGE 149 enrolled; VOYAGE 214; PANORAMA >200) and were powered around a 5‑point placebo‑adjusted difference (VOYAGE/PANORAMA >99% power; EMERGE 80% with ~3‑point significance threshold), which management says targets clinically meaningful and durable single‑dose effects.
• Each study includes a Part B with up to one year of follow‑up and up to four open‑label retreatments triggered at moderate symptoms, intended to characterize retreatment patterns, durability, and longer‑term safety for potential labeling discussions.
• The company ended Q1 with $373.4 million in cash and investments, which management believes provides runway to fund planned operations through multiple pivotal readouts and into 2028.
• Near‑term spend ramped materially — Q1 R&D rose to $41.5M and G&A to $17.7M versus prior year — contributing to a wider net loss of $77.1M, with a $20M quarterly impact from warrant fair‑value movement, indicating higher cash burn and elevated execution costs ahead.

Definium Therapeutics Trading Down 5.0%

Shares of NASDAQ DFTX traded down $1.15 during trading hours on Friday, hitting $22.05. The company’s stock had a trading volume of 2,203,452 shares, compared to its average volume of 1,963,772. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -8.86 and a beta of 2.37. Definium Therapeutics has a 12 month low of $6.03 and a 12 month high of $26.25. The business has a 50-day simple moving average of $19.98 and a 200-day simple moving average of $16.05.

Institutional Trading of Definium Therapeutics

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares during the last quarter. Caxton Associates LLP bought a new stake in shares of Definium Therapeutics in the third quarter worth about $126,000. Mercer Global Advisors Inc. ADV grew its stake in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after purchasing an additional 2,079 shares during the last quarter. Finally, Scientech Research LLC bought a new stake in shares of Definium Therapeutics in the third quarter worth about $286,000. 27.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DFTX shares. HC Wainwright raised their price objective on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Wolfe Research started coverage on Definium Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $25.00 price objective on the stock. Jefferies Financial Group started coverage on Definium Therapeutics in a research note on Thursday, January 29th. They set a “buy” rating and a $30.00 price objective on the stock. Leerink Partners raised their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Finally, Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a research note on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $37.92.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.